Advertisement

Topics

Pacira Raises Wall Street Expectations of a New Blockbuster Painkiller

10:53 EDT 19 May 2011 |

The last time Xconomy checked in with Pacira Pharmaceuticals (NASDAQ: PCRX), in early 2009, the company was laying off a third of its workforce in the wake of a disappointing clinical trial of Exparel, a treatment for post-surgical pain. Pacira was capital-constrained because the market for life-sciences IPOs was all but dead. And the future [...]

Original Article: Pacira Raises Wall Street Expectations of a New Blockbuster Painkiller

NEXT ARTICLE

More From BioPortfolio on "Pacira Raises Wall Street Expectations of a New Blockbuster Painkiller"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Pain
Pain is defined by the International Association for the Study of Pain as “an unpleasant sensory and emotional experience associated with actual or potential tissue damage or described in terms of such damage”. Some illnesses can be excruci...